Feedback / Questions
AFNT-111 - Affini-T Therap, Erasca
TP53 R175H-targeting TCR T - Affini-T Therap
AFNT-212 - Affini-T Therap
AFNT-211 - Affini-T Therap
https://www.businesswire.com/news/home/20241106297988/en/Affini-T-Therapeutics-to-Present-Trial-in-Progress-Poster-and-Preclinical-Data-from-Its-Oncogenic-Driver-Programs-Targeting-TP53-R175H-KRAS-G12D-and-KRAS-G12V-at-the-Society-for-Immunotherapy-of-Cancer-SITC-39th-Annual-Meeting
Nov 6, 2024
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next